Q2 EPS Forecast for Syndax Pharmaceuticals Lifted by Analyst

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at B. Riley boosted their Q2 2025 earnings estimates for shares of Syndax Pharmaceuticals in a research report issued on Tuesday, May 6th. B. Riley analyst K. Patel now expects that the company will earn ($0.93) per share for the quarter, up from their prior estimate of ($1.11). The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals' Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($3.35) EPS, FY2026 earnings at ($2.11) EPS and FY2027 earnings at ($0.99) EPS.

SNDX has been the topic of a number of other research reports. HC Wainwright reissued a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. StockNews.com upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday. Guggenheim reissued a "buy" rating and set a $32.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday. Scotiabank lifted their price objective on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $35.91.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock traded down $0.31 during midday trading on Thursday, reaching $10.70. 2,336,266 shares of the company were exchanged, compared to its average volume of 1,688,715. Syndax Pharmaceuticals has a 12 month low of $9.66 and a 12 month high of $25.07. The company has a market cap of $920.67 million, a P/E ratio of -2.95 and a beta of 0.82. The company's 50 day moving average price is $12.48 and its two-hundred day moving average price is $14.42.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The business had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. The business's quarterly revenue was up 1900.0% compared to the same quarter last year. During the same period last year, the company earned ($0.85) earnings per share.

Institutional Trading of Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SNDX. Franklin Resources Inc. increased its position in Syndax Pharmaceuticals by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock worth $34,948,000 after buying an additional 208,043 shares during the period. Barclays PLC increased its position in Syndax Pharmaceuticals by 143.4% during the third quarter. Barclays PLC now owns 187,629 shares of the company's stock worth $3,612,000 after acquiring an additional 110,535 shares during the period. Jump Financial LLC raised its stake in Syndax Pharmaceuticals by 80.8% in the 4th quarter. Jump Financial LLC now owns 173,890 shares of the company's stock worth $2,299,000 after purchasing an additional 77,699 shares in the last quarter. Simplify Asset Management Inc. boosted its holdings in Syndax Pharmaceuticals by 20.8% in the 4th quarter. Simplify Asset Management Inc. now owns 147,641 shares of the company's stock valued at $1,952,000 after purchasing an additional 25,456 shares during the period. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Syndax Pharmaceuticals by 343.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock worth $27,292,000 after purchasing an additional 1,598,428 shares during the period.

Insider Activity

In other news, CEO Michael A. Metzger sold 13,288 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the sale, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This represents a 4.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Neil Gallagher sold 4,618 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now directly owns 85,095 shares of the company's stock, valued at $1,318,972.50. This represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock worth $336,087 over the last ninety days. Insiders own 4.10% of the company's stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).